Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258180 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00258180: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00258180 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258180, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2005-08-15 |
| Est. Completion | 2009-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258180
The ClinicalTrials.gov registry entry for NCT00258180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00258180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258180 about?
NCT00258180 is a clinical study titled "Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy". RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
What is the current status of trial NCT00258180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2005-08-15. Estimated completion is 2009-02-24.
What interventions are being tested in trial NCT00258180?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258180?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.